GSK (GSK, GSK.L) has commenced the distribution of trivalent influenza vaccines to healthcare providers and pharmacies across the United States, gearing up for the 2024-25 flu season. This follows the recent licensing and lot-release approval from the FDA. GSK plans to distribute over 36 million doses in the U.S.
Both FLULAVAL and FLUARIX vaccines will be available in a 0.5mL, single-dose, pre-filled syringe and are recommended for individuals aged six months and older. These vaccines are designed for active immunization against the influenza A subtype viruses and type B virus included in the formulations.
